SCHEMBL20530645

SCHEMBL20530645

COc1ccc(-c2cccc(CO)c2)c(CNC(=O)OCC2c3ccccc3-c3ccccc32)c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 1/20 0.44
EPHX2 P34913 1/20 0.41
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
MTNR1A P48039 5/20 0.41
MTNR1B P49286 5/20 0.41
KMT2A Q03164 2/20 0.41
MDM2 Q00987 1/20 0.40
EPHX1 P07099 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38
DRD2 P14416 1/20 0.38
DRD1 P21728 1/20 0.38
DRD4 P21917 1/20 0.38
DRD5 P21918 1/20 0.38
HTR2A P28223 1/20 0.38
ADRA1A P35348 1/20 0.38
DRD3 P35462 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20530629 0.89 CHRM3 (0.45) CHRM3EPHX2KMT2AMDM2EPHX1
SCHEMBL20530627 0.88 EPHX2 (0.47) CHRM3EPHX2KMT2AEPHX1
SCHEMBL29639572 0.87 EPHX2 (0.43) CHRM3EPHX2KMT2AEPHX1
SCHEMBL30466805 0.86 MTNR1A (0.42) EPHX2TAS1R3TAS1R1MTNR1AMTNR1B
SCHEMBL20530643 0.86 MTNR1A (0.42) EPHX2TAS1R3TAS1R1MTNR1AMTNR1B
SCHEMBL20530641 0.84 PTGDR2 (0.45) CHRM3EPHX2KMT2AMDM2
SCHEMBL29639583 0.81 EPHX1 (0.43) CHRM3EPHX2KMT2AEPHX1
SCHEMBL18688054 0.80 EPHX2 (0.53) CHRM3EPHX2KMT2AEPHX1
SCHEMBL20530618 0.79 EPHX2 (0.44) CHRM3EPHX2KMT2AEPHX1
SCHEMBL20530673 0.79 KMT2A (0.42) CHRM3EPHX2KMT2AMDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110494442-B Peptide macrocycles and their use in the treatment of bacterial infections 豪夫迈·罗氏有限公司 2023-07-25 CN disclosed
EP-3609905-B1 PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS HOFFMANN LA ROCHE (CH) 2022-06-08 EP disclosed
US-11091514-B2 Peptide macrocycles and use thereof in the treatment of bacterial infections HOFFMANN-LA ROCHE INC. (US) 2021-08-17 US disclosed
EP-3609905-A1 PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS H. Hoffnabb-La Roche Ag (CH) 2020-02-19 EP disclosed
US-20200040032-A1 PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS HOFFMANN-LA ROCHE INC. (US) 2020-02-06 US disclosed
WO-2018189063-A1 PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS F. HOFFMANN-LA ROCHE AG (CH) 2018-10-18 WO disclosed
EP-3388445-A1 PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS F. Hoffmann-La Roche AG (CH) 2018-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091514-B2 Peptide macrocycles and use thereof in the treatment of bacterial infections VIP, NPY5R, CXCR3 CHRM3 415/4885EPHX2 3891/4885TAS1R3 585/4885
US-20200040032-A1 PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS VIP, NPY5R, CXCR3 CHRM3 415/4885EPHX2 3891/4885TAS1R3 585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.